Hyperhidrosis Treatments

Find Hyperhidrosis Treatments

Brand Name

Qbrexza

Generic Name

Glycopyrronium

View Brand Information

FDA approval date: June 28, 2018

Classification: Cholinergic Muscarinic Antagonist

Form: Cloth

What is Qbrexza (Glycopyrronium)?

Qbrexza is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older .

Approved To Treat

Hyperhidrosis

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation

Enrollment Status: Recruiting

Publish Date: April 15, 2026

Intervention Type: Device, Drug

Study Phase: Phase 4

Summary: The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.

A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Bromide) in Children From 6 to Less Than 12 Years of Age With Asthma.

Who is this study for: Children from 6 to less than 12 years of age with asthma

Enrollment Status: Recruiting

Publish Date: March 30, 2026

Intervention Type: Drug

Study Drug: Glycopyrronium bromide

Study Phase: Phase 2

Summary: The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 1...

Post-marketing Phase IV, Multicenter, Prospective Study to Observe the Safety and Tolerability of Breztri aerosphereTM Containing a Fixed Dose Combination of Budesonide 160 mcg/ Glycopyrronium 7.2 mcg/ Formoterol Fumarate Dehydrate 5 mcg in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Enrollment Status: Recruiting

Publish Date: March 18, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.

View All Clinical Trials

Related Latest Advances

Advances in pharmacological treatment and management of hyperhidrosis.

Journal: Expert opinion on pharmacotherapy

Published: March 23, 2026

A 17-year-old boy with hemifacial flushing and anhidrosis.

Journal: JAAD case reports

Published: March 20, 2026

Advances in the Management of Hyperhidrosis.

Journal: Skin therapy letter

Published: March 16, 2026

View All Latest Advances